A company that develops a product would earn a share of reward money based on its share of the health improvements achieved by all the products competing for the available funds. What is still needed, however, is sufficient reward money – perhaps $100 million from governments, NGOs, foundations and the pharmaceutical industry – to stimulate serious investment.